Trial Profile
Phase Ib Trial of Dose-escalating AZD1775 in Combination With Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 11 Aug 2021 Results assessing safety and efficacy of adavosertib in combination with definitive chemoradiotherapy for patients with newly diagnosed, intermediate-risk or high-risk, locally advanced head and neck squamous cell carcinoma, published in the Cancer.
- 05 Jan 2021 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Status changed from recruiting to active, no longer recruiting.